Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 52

1 329 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 329
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 329 trials in Lille

Open in trial search

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Neoplasm malignant+1

Not yet recruiting

Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Osteomyelitis

Not yet recruiting

Zoledronic acid versus placebo for pain relief in children with chronic recurrent multifocal osteomyelitis resistant to NSAIDs

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Zoledronic Acid
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Craniopharyngioma

Not yet recruiting

A study to evaluate the effectiveness of semaglutide for treating obesity caused by craniopharyngioma in children aged 12 to 17 years.

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Vulval cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imiquimod
  • Sponsor:Centre Leon Berard

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Mechanical ventilation

Not yet recruiting

Study of ketamine hydrochloride to improve recovery in adults requiring unplanned mechanical ventilation in the intensive care unit

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Graft versus host disease

Not yet recruiting

Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vancomycin
  • Sponsor:Maat Pharma

Interstitial lung disease+2

Not yet recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.